METHOTREXATE DISODIUM

DRUG6 trials

Sponsors

Universitaetsklinikum Erlangen AöR, Medical Center - University Of Freiburg, Fundacion Para La Investigacion Biomedica Del Hospital Clinico San Carlos, Klinikum Der Landeshauptstadt Stuttgart gKAöR, Medical University Of Silesia Katowice Poland

Conditions

Acute lymphoblastic leukemiaNon-infection uveitisPrimary diffuse large B-cell lymphoma (DLBCL) of the central nervous system is a rare disorder confined to the cerebral parenchymaPrimary diffuse large B-cell lymphoma of the central nervous system (PCNSL) is a rare lymphoma affecting only the central nervous system compartment. PCNSL patients are typically 60 years or older and have poor prognoses. Considering the poor prognosis of this patient populationPsoriatic arthritiseyes or spinal cord. It accounts for 4 to 6% of all Non- Hodgkin's lymphomas and for 3 to 4% of all primary brain tumors. Incidence of PCNSL has increased over the past 30 yearsleptomeningesparticularly in immunocompetent individuals. With a median survival of 3 months in untreated individuals

Phase 2

Ruxolitinib for childhood ALL in Poland (Rux-cALL-Pol 2020 trial) - Single-arm interventional study with ruxolitinib and AIEOP-BFM 2017 Poland or AIEOP-BFM 2017 standard of care chemotherapy in children with acute lymphoblastic leukemia and confirmed activation of JAK/STAT pathway.

Not yet recruitingCTIS2024-518316-39-00

Medical University Of LodzAcute lymphoblastic leukemia

Target: 25Updated: 2025-04-04

Phase 3

A prospective, randomized, controlled, open label, assessor-blinded, parallel-group Phase III clinical trial to evaluate the impact of tapering systemic immunosuppressive therapy in a treat-to-target approach on maintaining minimal disease activity in adult subjects with psoriatic arthritis

RecruitingCTIS2023-508251-39-00

Universitaetsklinikum Erlangen AöRPsoriatic arthritis

Start: 2020-09-18Target: 370Updated: 2026-01-20

CO-THEIA (COMBINATION THERAPY WITH METHOTREXATE AND ADALIMUMAB FOR UVEITIS): EFFICACY, SAFETY AND COST-EFFECTIVENESS OF METHOTREXATE, ADALIMUMAB, OR THEIR COMBINATION IN NON INFECTIOUS NON ANTERIOR UVEITIS: A MULTICENTER, RANDOMIZED, PARALLEL 3 ARMS, ACTIVE-CONTROLLED, PHASE 3 OPEN LABEL WITH BLINDED OUTCOME ASSESSMENT STUDY.

CompletedCTIS2024-513123-17-00

Fundacion Para La Investigacion Biomedica Del Hospital Clinico San CarlosNon-infection uveitis

Start: 2022-01-12End: 2025-11-26Target: 192Updated: 2025-03-03

Age-adjusted high-dose chemotherapy followed by autologous stem cell transplantation or conventional chemotherapy with R-MP as first-line treatment in elderly primary CNS lymphoma patients – a randomized phase III trial - PRIMA-CNS

RecruitingCTIS2024-512320-11-00

Medical Center - University Of FreiburgPrimary diffuse large B-cell lymphoma of the central nervous system (PCNSL) is a rare lymphoma affecting only the central nervous system compartment. PCNSL patients are typically 60 years or older and have poor prognoses. Considering the poor prognosis of this patient population, this randomised phase III trial proposal is of great clinical importance to provide patients optimal treatment.

Start: 2023-08-09Target: 260Updated: 2025-12-22

Collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia. A randomized phase III study conducted in agreement with the AIEOP-BFM study group.

Active, not recruitingCTIS2024-517253-27-00

Medical University Of Silesia Katowice PolandAcute lymphoblastic leukemia

Start: 2021-07-01Target: 874Updated: 2024-10-28

Optimizing MATRix as remission induction in PCNSL: De-escalated induction treatment in newly diagnosed primary CNS lymphoma – a randomized phase III trial

RecruitingCTIS2024-514473-21-00

Klinikum Der Landeshauptstadt Stuttgart gKAöReyes or spinal cord. It accounts for 4 to 6% of all Non- Hodgkin's lymphomas and for 3 to 4% of all primary brain tumors. Incidence of PCNSL has increased over the past 30 years, leptomeninges, particularly in immunocompetent individuals. With a median survival of 3 months in untreated individuals +2

Start: 2021-06-21Target: 286Updated: 2025-11-26